Webinar on PolarisDMD: Phase 3 Clinical Trial of Edasalonexent
CAMBRIDGE, Mass., November 2, 2018 – Catabasis Pharmaceuticals, Inc (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Parent Project Muscular Dystrophy (PPMD) will host a webinar: “PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor, in Duchenne Muscular Dystrophy,” on Wednesday, November 7, 2018 at 1:00pm ET.
Pat Furlong, Founding President and Chief Executive Officer, Parent Project Muscular DystrophyDr. Donovan will discuss the Phase 3 PolarisDMD clinical trial studying edasalonexent in Duchenne muscular dystrophy (DMD), which is enrolling boys ages 4 to 7 (up to 8th birthday) regardless of mutation type who have not been on steroids for at least 6 months. Topics will include discussion of the PolarisDMD clinical trial, endpoints, inclusion and exclusion criteria, and information on edasalonexent, including previous clinical results that showed preserved muscle function in boys affected by Duchenne with edasalonexent treatment compared to the off-treatment period as well as significantly improved biomarkers.The webinar can be accessed by visiting http://bit.ly/2Puskwr.